Ann: GlaxoSmithKline Extends Service Agreement with MedAdvisor-MDR.AX, page-2

  1. 32 Posts.
    Highlights
    • GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months
    • GSK will continue utilising MedAdvisor’s medication management platform to to provide relevant information for patients prescribed three medicines within GSK Australia’s respiratory portfolio.
    • Agreement will generate Patient Engagement Program (PEP), formerly known as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
    • Allows GSK Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
6.0¢
Change
0.004(7.14%)
Mkt cap ! $37.48M
Open High Low Value Volume
5.8¢ 6.0¢ 5.6¢ $86.07K 1.481M

Buyers (Bids)

No. Vol. Price($)
1 53985 5.8¢
 

Sellers (Offers)

Price($) Vol. No.
6.0¢ 245549 2
View Market Depth
Last trade - 16.10pm 14/07/2025 (20 minute delay) ?
MDR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.